A prospective cohort study assessing the safety and effectiveness of treatment for HCV genotypes 1a and 1b infected patients with these DAAs (Daclatasvir, Simeprevir and Sofosbuvir with or without Ribavirin) in Brazilian population
Latest Information Update: 21 Sep 2021
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2021 New trial record